GRI Bio, Inc.

GRI Healthcare Biotechnology

In the quarter to June 2026, EPS grew 97.5% and free cash flow grew 54.3%, each against the same quarter a year earlier.

1.38 0.02 −1.43%
Market cap
$3.1M
P/E
0.0×
Fwd P/E
−4.2×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(465.42%) (238.17%) (185.67%) (142.02%)
ROA
(256.91%) (166.00%) (141.84%) (113.27%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(678.44%) (200.87%) (104.01%) (94.36%)
Free Cash Flow per Share
(98.44) (103.84) (9.78) (5.77)
Free Cash Flow
(9.21) (10.20) (12.13) (10.41)
Other line items

Show all line items

Columns are period end dates